Metastatic Castration-Resistant Prostate Cancer Gets New Therapy, As FDA Approves XTANDI

Metastatic Castration-Resistant Prostate Cancer Gets New Therapy, As FDA Approves XTANDI
Astellas Pharma Inc. and Medivation, Inc. have announced that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI® (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (mCRPC). This new approval is based on a priority review of the supplemental New Drug Application (sNDA) that was based on

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *